Serosurvey of SARS-CoV-2 Antibodies After Omicron Outbreak at a University
Author Information
Author(s): Hou Ching-Wen, Williams Stacy, Trivino-Soto Guillermo, Boyle Veronica, Rainford David, Vicino Selina, Magee Mitch, Chung Yunro, LaBaer Joshua, Murugan Vel
Primary Institution: Arizona State University
Hypothesis
What is the seroprevalence of SARS-CoV-2 antibodies among individuals aged 18 years and older after the Omicron outbreak?
Conclusion
The study found a seroprevalence of 96.3% for anti-RBD antibodies and 39.1% for anti-NC antibodies among participants after the Omicron outbreak.
Supporting Evidence
- 96.3% of participants tested positive for anti-RBD antibodies.
- 39.1% of participants tested positive for anti-NC antibodies.
- Participants with breakthrough infections had higher antibody levels.
- Saliva samples showed strong agreement with serum samples for antibody levels.
- Seroprevalence increased significantly from the previous survey conducted before the Omicron outbreak.
Takeaway
Most people at the university had antibodies against COVID-19 after the Omicron variant spread, showing that many were either vaccinated or had been infected.
Methodology
Participants aged 18 and older were recruited for a seroprevalence study, providing blood and saliva samples for antibody testing.
Potential Biases
Potential selection bias due to participants' willingness to join the study.
Limitations
The study relied on self-reported data for vaccination and infection history, which may introduce bias.
Participant Demographics
Participants included 58.7% students and 40.2% employees, with a majority aged 18-25.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI 95.2–97.2%
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website